Rebalix
Xtrackers · sheet of 10 September 2026
Xtrackers · sheet of 10 September 2026ETF sheet · official issuer and register data
Xtrackers Msci Genomic Healthcare Innovation UCITS ETF 1c
IE000KD0BZ68 · IE000KD0BZ68 · USD · domicile Ireland
Equity · Global · Health care · All sizes · Sustainable / ESG · ThematicSFDR art. 8
Index tracked: MSCI ACWI IMI Genomic Innovation Select Screened 100 Index (USD)
- TER
- 0.30%+ trans. 0.06%
- Fund size
- 9 m EUR
- Tracking difference
- −0.24%3-year avg
- 🇮🇹 tax rate
- —white list not published
- Replication
- Physical
- Income
- Accumulating
Launch 12 Jul 2022 · costs from the KID as of 2 Sept 2026 · 117 securities held · 9 venues (ESMA register)
The fund’s objective — in the issuer’s words
From the Key Information Document (KID) · 4 Aug 2026
The fund is passively managed.
INVESTMENT OBJECTIVE:
The aim is for your investment to track the performance before fees and expenses of the MSCI ACWI IMI Genomic Innovation Select Screened 100 Index (index).
DESCRIPTION OF INDEX:
The index is based on the MSCI ACWI IMI Index (Parent Index) and reflects the performance of large, medium, and small-capitalisation companies globally that derive, or are expected to derive, significant revenues from technological innovation in the genomic healthcare sector. Companies from the Parent Index that pass both…
Performance since series start (in euro) — base 100
12 Jul 2022 → 8 Sept 2026 · dividends reinvested where declared by the issuer · converted at ECB rates
Returns in euro
| 1 year | +37.1% |
| 3 years | +35.1% |
| 5 years | series too young |
| 10 years | series too young |
| Since series start | +12.0% |
Risk · 1 / 3 / 5 years
| Volatility (ann.) | 22.10% | 19.61% | — |
| Max drawdown | −14.71% | −24.28% | — |
| Sharpe | 1.40 | 0.57 | — |
| Sortino | 2.44 | 0.86 | — |
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · IE000KD0BZ68 · IE000KD0BZ681
RebalixIE000KD0BZ68 · IE000KD0BZ68 · sheet of 10 September 2026
Tracking difference — year by year
Fund minus index, complete calendar years · from issuer-declared series
| Year | Fund | Index | TD |
|---|---|---|---|
| 2025 | +19.29% | +19.54% | −0.25% |
| 2024 | −2.24% | −2.10% | −0.14% |
| 2023 | −3.72% | −3.39% | −0.33% |
Holdings
Portfolio as declared by the issuer · 2 Sept 2026 · 117 securities · top-10 weight = 43.0%
| Top holdings | Weight |
|---|---|
| 4.6% | |
| 4.5% | |
| 4.5% | |
| 4.5% | |
| 4.4% | |
| 4.4% | |
| 4.3% | |
| 4.1% | |
| 4.0% | |
| 3.8% |
Countries (% of fund)
Sectors (% of fund)
Listing venues
ESMA register (FIRDS) and official exchange lists
XGEN · Borsa Italiana (ETFplus), Börse Düsseldorf, Börse Frankfurt, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Tradegate Exchange, Xetra (Deutsche Börse)
+ 5 unmapped venues (MTF, RFQ, professional)
Official documents
Clickable links in the PDF
The live sheet, always up to date
rebalix.com/en/etf/IE000KD0BZ68
Series, distributions, holdings and documents refresh daily.
rebalix.com/en/etf/IE000KD0BZ68
Series, distributions, holdings and documents refresh daily.
Sheet produced on 10 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.
Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.
Rebalix · IE000KD0BZ68 · IE000KD0BZ682